---
title: "Compass Showcases Promising Tovecimig Data, Eyes Commercialization"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291469511.md"
description: "Compass Therapeutics (CMPX) highlighted promising Phase 2/3 data for its lead drug tovecimig in biliary tract cancer, showing superior response rates with paclitaxel. The company outlined plans for late-stage development and potential commercialization, with a cash runway into 2028. While analysts maintain a 'Buy' rating with a $7 target, TipRanks' AI tool rates the stock as 'Neutral' due to pre-revenue status and persistent losses, despite positive clinical news."
datetime: "2026-07-01T21:30:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291469511.md)
  - [en](https://longbridge.com/en/news/291469511.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291469511.md)
generator: "portal-rs"
---

# Compass Showcases Promising Tovecimig Data, Eyes Commercialization

Compass Therapeutics ( (CMPX) ) has shared an announcement.

On July 1, 2026, Compass Therapeutics updated its corporate presentation to highlight new data from the COMPANION-002 Phase 2/3 trial of its lead drug candidate tovecimig in second-line biliary tract cancer, where the combination of tovecimig and paclitaxel achieved a significantly higher overall response rate than paclitaxel alone in a 168-patient study. The company detailed a late-stage development and regulatory plan for tovecimig, supported by prior monotherapy and combination data in multiple refractory tumor types, and outlined a diversified oncology pipeline and cash runway into 2028 as it prepares for potential commercialization and multiple clinical milestones over 2026–2027.

The most recent analyst rating on (CMPX) stock is a Buy  
 with a $7.00 price target.  
 To see the full list of analyst forecasts on Compass Therapeutics stock,  
 see the CMPX Stock Forecast page. 

**Spark’s Take on CMPX Stock**

According to Spark, TipRanks’ AI Analyst, CMPX is a Neutral.

The score is held down primarily by weak financial performance (pre-revenue status, persistent losses, and continued cash burn) and a technically weak price trend below major moving averages. Positive clinical-trial news provides a meaningful offset, but current unprofitability (negative P/E) and lack of dividend support keep the overall profile speculative.

To see Spark’s full report on CMPX stock,  
 click here. 

**More about Compass Therapeutics**

Compass Therapeutics, Inc. is a biotechnology company focused on developing next-generation oncology therapies, notably bispecific antibodies and other immune-oncology agents. Its lead asset, tovecimig, is a DLL4 x VEGF-A bispecific antibody positioned as a next-generation angiogenesis inhibitor, targeting solid tumors including biliary tract cancer and other gastrointestinal and gynecologic malignancies.

**Average Trading Volume:** 8,132,722

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $394.4M

Find detailed analytics on CMPX stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

- [Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026 | CMPX Stock News](https://longbridge.com/en/news/293052670.md)
- [Security Risk Advisors Launches SCALR AI as a Free SOC AI Platform for Security Teams](https://longbridge.com/en/news/297523531.md)
- [Mamdani is putting AI on recess for 600,000 students](https://longbridge.com/en/news/297813637.md)
- [Alset AI Ventures Inc. GAAP EPS of $0.19](https://longbridge.com/en/news/297563122.md)
- [Cogent Biosciences Secures Long-Term Bezuclastinib Supply Deal](https://longbridge.com/en/news/297839428.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**